| 查看: 525 | 回复: 1 | |||
ienjoysun银虫 (著名写手)
|
[交流]
Devices will play a key role in evolution of GLP-1 market 已有1人参与
|
|
Physician Views Poll Results: Devices will play a key role in evolution of GLP-1 market, say endocrinologists; expect boost to Bydureon sales once new pen launched (Ref: Physician Views Desk) March 7th, 2014 By: Simon King Tags: Physician Views Poll Results albiglutide Bydureon dulaglutide Lyxumia Victoza AstraZeneca GSK Lilly Novo Nordisk Sanofi Diabetes General Practice Internal Medicine Clinical Research (R&D) Marketing & Sales Medical Affairs Regulatory Affairs Feedback from endocrinologists based in both the US (n=41) and EU5 (n=36) suggests that injection devices will play a key role in shaping the future development of the market for GLP-1 agonist anti-diabetic products. Supporting the view from key opinion leaders (KOLs) previously interviewed by FirstWord's Therapy Trends team, 30 percent of all respondents said that injectable administration of the GLP-1 class has played a 'significant' role in reducing their usage of, and/or patient preference for, these products. Furthermore, 25 percent of respondents said that the need to inject these therapies had caused a 'notable' impact on uptake of GLP-1 agonists to date, while a further 30 percent described this impact as being 'moderate.' The view that an injectable means of administration has acted as a barrier to uptake was more pronounced among endocrinologists from the EU5. In the case of AstraZeneca's Bydureon (the first once-weekly GLP-1 agonist to reach the market), this issue is more pronounced. The requirement for patients to implement a six-stage reconstitution process prior to administration has been largely cited as limiting the commercial performance of Bydureon to date; a scenario not helped by the device also having a larger needle than competitor products. On the issue of Bydureon use, 18 percent of all respondents cited the necessary reconstitution process as typically being the primary factor in cases where they have previously prescribed an alternative GLP-1agonist, while a further 8 percent cited the large needle size. AstraZeneca is seeking to overcome one of these barriers-to-uptake via the launch of a new pen (approved by the FDA last week) that is ready-to-use and does not require the patient to mix the product prior to usage. Endocrinologists suggested on average that availability of their device would see them increase their usage of Bydureon by around 30 percent. That said, physician responses pertaining as to why they have used alternative GLP-1 agonists historically indicates that perceived efficacy and formulary placement/reimbursement status will remain key issues that AstraZeneca will need to negotiate if it is to meaningfully boost sales of Bydureon – see Spotlight On: Too little too late? – Intensifying competition and pricing pressure likely to limit AstraZeneca's progress via new Bydureon device. The competitive landscape is expected to intensify, particularly if Eli Lilly's dulaglutide is launched in the US market towards the end of the year as expected. Clearly perceiving the pen device for these products to be an integral element of the commercial narrative, Eli Lilly has designed a device that does not require the patient to either see or touch the needle that is used to inject dulaglutide. Nearly a quarter of all endocrinologists polled by FirstWord said that such a device would provide a 'significant' advantage, while 34 percent and 19 percent of respondents suggested it would confer a 'notable' and 'moderate' benefit, respectively. Overall, 32 percent of endocrinologists suggested that superior delivery devices would play an integral role in shaping prescription trends 'given that the clinical profiles of these products are broadly similar.' Furthermore, 27 percent of respondents said that such devices were important as ' route of administration (i.e. injection) acts to reduce usage of this drug class as a whole.' Eighteen percent of respondents said that the devices were integral, but not as important as other factors in actually dictating usage, while a further 18 percent described them as being 'nice to have' rather than integral. Interestingly, just 4 percent of endocrinologists were largely dismissive of device design altogether in light of other factors such as formulary placement or reimbursement status. With this in mind, investors and analysts will be watching carefully to see if AstraZeneca's more convenient injector pen can have a short-term impact on the performance of Bydureon. DOWNLOAD POLL RESULTS As always, FirstWord would very much like to receive your feedback and suggestions. Note: FirstWord Polls are powered by MedePolls, a fast-turnaround service to conduct instant polls of up to five questions with guaranteed samples that include physicians from dozens of specialities and over 100 markets (for further information click here). To conduct this poll with a different audience, or an entirely different poll, contact us at info@firstwordpharma.com. |
回复此楼» 猜你喜欢
海勃原辅料助力银屑病一线外用制剂开发
已经有0人回复
-
二乙烯基砜的合成路径
已经有4人回复
-
药理学论文润色/翻译怎么收费?
已经有105人回复
-
求一株[b]敲除MTAP(human)的HCT-116(人结肠癌细胞)/b]细胞
已经有0人回复
-
求助！求美国食品化学药典内容：FCC13【低聚果糖专论】
已经有0人回复
-
【2027博士申请】纳米药物递送方向
已经有5人回复
-
消耗微量API，便可预测早期研发阶段的HME工艺可行性
已经有0人回复
-
反应液中苯酐除去
已经有1人回复
-
2026生物医药产业发展大会
已经有0人回复
2楼2014-03-27 17:07:16
40